Phase-I Study of the new B-Cell Lymphoma 2 (BCL2) Inhibitor BGB-11417 as Monotherapy or in Combination with Zanubrutinib (zanu) in Patients (pat) with B-Cell Malignancies: preliminary Data

被引：0

作者：

Stilgenbauer, S. ^{[1
]}

Opat, S. ^{[2
,3
]}

Cheah, C. Y. ^{[4
,5
,6
,7
]}

Lasica, M. ^{[8
]}

Verner, E. ^{[9
,10
]}

Browett, P. J. ^{[11
]}

Chan, H. ^{[12
]}

Soumerai, J. D. ^{[13
]}

Gonzalez, Barca E. ^{[14
]}

Hilger, J. ^{[15
]}

Fang, Y. ^{[16
]}

Simpson, D. ^{[15
]}

Tam, C. S. ^{[17
,18
,19
]}

机构：

[1] Univ Ulm, Ulm, Germany

[2] Monash Hlth, Clayton, Australia

[3] Monash Univ, Clayton, Australia

[4] Sir Charles Gairdner Hosp, Nedlands, Australia

[5] Pathwest Lab Med, Nedlands, Australia

[6] Univ Western Australia, Sch Med, Crawley, Australia

[7] Linear Clin Res, Nedlands, Australia

[8] St Vincents Hosp Melbourne, Fitzroy, Australia

[9] Concord Repatriat Gen Hosp, Concord, Australia

[10] Univ Sydney, Sydney, Australia

[11] Auckland City Hosp, Auckland, New Zealand

[12] North Shore Hosp, Auckland, New Zealand

[13] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA

[14] Univ Barcelona, Inst Catala Oncol Hosp, Barcelona, Spain

[15] BeiGene USA Inc, San Mateo, CA USA

[16] BeiGene Beijing Co Ltd, Beijing, Peoples R China

[17] Peter MacCallum Canc Ctr, Melbourne, Australia

[18] Univ Melbourne, Parkville, Australia

[19] Royal Melbourne Hosp, Parkville, Australia

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 2期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V91

引用

页码：30 / 30

页数：1